Malignant hypertension: A rare problem or is it underdiagnosed?

Current Vascular Pharmacology

Volumn 8, Issue 6, 2010, Pages 775-779

  Shantsila, Alena ^a   Shantsila, Eduard ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Hypertensive encephalopathy; Maligant hypertension; Renal failure

Indexed keywords

ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DEVELOPING COUNTRY; DIASTOLIC BLOOD PRESSURE; HUMAN; HYPERTENSION ENCEPHALOPATHY; HYPERTENSION RETINOPATHY; INCIDENCE; MALIGNANT HYPERTENSION; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS; RETROSPECTIVE STUDY; STROKE; SYSTOLIC BLOOD PRESSURE;

EID: 78649363400     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016110793563834     Document Type: Article

References (38)

1. Lip GYH, Lane V, Agashi S, Elliot A, Beevers M, Beevers G. Incidence of maligant phase hypertension in a multiethnic population: the West Birmingham malignant hypertension register. Am J Hypertens 2003; 16 (Suppl 1): A213
2. Seedat YK. Renal status of malignant-accelerated hypertension in he developing countries. Am J Hypertens 2004; 17 (Suppl 1): S94
3. Libório AB, Marques Fde O, Testagrossa L, Leite CA, Leitão AA, Praxedes JN. Malignant hypertension with intestinal ischemia secondary to juxtaglomerular cell tumor. Am J Kidney Dis 2005; 46: 957-961
4. Moorthy N, Prasad BN, Kumar YC, Kumar ML, Prathima KM. Malignant hypertension, dissection of aorta, cardiac tamponade and monoparesis-unusual presentation of Takayasu's arteritis: clinicopathological correlation. Int J Cardiol 2009; 133: e114-117
5. Petitti DB, Klatsky AL. Malignant hypertension in women aged 15 to 44 years and its relation to cigarette smoking and oral contraceptives. Am J Cardiol 1983; 52: 297-298
6. Tadokoro K, Nishikimi T, Mori Y, Wang X, Akimoto K, Matsuoka H. Altered gene expression of adrenomedullin and its receptor system and molecular forms of tissue adrenomedullin in left ventricular hypertrophy induced by malignant hypertension. Regul Pept 2003; 112: 71-78
7. Edmunds E, Li Saw Hee FL, Gurney D, Blann AD, Beevers DG, Lip GYH. Malignant phase hypertension is associated with endothelial dysfunction, platelet activation and elevated fibrinogen. Am J Hypertens 2000; 13: 237A-239A
8. Edmunds E, Li Saw Hee FL, Landray M, Beevers DG, Lip GYH. Malignant phase hypertension is associated with abnormalities of low density lipoprotein subfraction profiles. Am J Hypertens 2000;13: 109A-110A
9. Gudbrandsson T, Hansson L, Herlitz H, Andren L. Malignant hypertension. Improving prognosis in a rare disease. Acta Med Scand 1979; 206: 495-499
10. Lip GY, Beevers M, Beevers DG. Do patients with de novo hypertension differ from patients with previously known hypertension when malignant phase hypertension occurs? Am J Hypertens 2000; 13: 934-939
11. Calhoun DA, Jones D, Textor S, et al.; American Heart Association Professional Education Committee. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117: e510-526
12. Lip GY, Beevers M, Beevers G. The failure of malignant hypertension to decline: a survey of 24 years' experience in a multiracial population in England. J Hypertens 1994; 12: 1297-1305
13. Keith NM, Wagener HP, Barker NW. Some different types of essential hypertension: their course and prognosis. Am J Med Sci 1974; 268: 336-345
14. Leishman AW. Hypertension: treated and untreated; a study of 400 cases. Br Med J 1959; 1: 1361-1368
15. Kincaid-Smith P. Malignant hypertension. J Hypertens 1991; 9: 893-899
16. Kadiri S, Olutade BO, Osobamiro O. Factors influencing the development of malignant hypertension in Nigeria. J Hum Hypertens 2000; 14: 532
17. Kadiri S, Olutade BO. The clinical presentation of malignant hypertension in Nigerians. J Hum Hypertens 1991; 5: 339-343
18. Schachat PA. Medical Retina, St. Louis, Missouri, United States: Mosby, Inc. 2001; pp. 1404-1409
19. Keith NM, Wagener HP, Kernohan JW. The syndrome of malignant hypertension. Arch Intern Med 1928; 41: 141-188
20. World Health Organization. Arterial hypertension. World Health Organ Tech Rep Ser 1978; 628: 7-56
21. Ahmed ME, Walker J M, Beevers DG, Beevers M. Lack of difference between malignant and accelerated hypertension. Br Med J 1986; 292: 235-237
22. McGregor E, Isles CG, Jay J L, Lever AF, Murray GD. Retinal changes in malignant hypertension. Br Med J 1986; 63292: 233-234
23. Chen YH, Kuo HK, Kao ML. Malignant hypertensive retinopathy clinical and fundus manifestations in patients with new onset or acute exacerbation of chronic hypertension. Chang Gung Med J 2003; 26: 669-677
24. Browning AC, Mengher LS, Gregson RM, Amoaku WM. Visual outcome of malignant hypertension in young people. Arch Dis Child 2001; 85: 401-403
25. Heidbreder E, Huller U, Schafer B, Heidland A. Severe hypertensive retinopathy. Increased incidence in renoparenchymal hypertension. Am J Nephrol 1987; 7: 394-400
26. Hayreh S, Servais G, Virdi P, Macus M, Rojas P, Woolson R. Fundus lesions in malignant hypertension: III. Arterial blood pressure, biochemical, and fundus changes. Ophthalmology 1986; 93: 45-59
27. Hayreh S, Servais S, Virdi P. Fundus lesions in malignant hypertension: IV Focal intraretinal periarterial transudates. Ophthalmology 1986; 93: 60-73
28. Lip GYH, Beevers M, Beevers DG. Survival and prognosis of 315 patients with malignant-phase hypertension. J Hypertens 1995; 13: 915-924
29. Shapiro LM, MacKinnon J, Beevers DG. Echocardiographic features of malignant hypertension. Br Heart J 1981; 46: 374-379
30. Davies DL, Beevers DG, Briggs JD, et al. Abnormal relation between exchangeable sodium and the renin-angiotensin system in MHT and in hypertension with chronic renal failure. Lancet 1973; 1: 683-686
31. van den Born BJ, Koopmans RP, van Montfrans GA. The reninangiotensin system in malignant hypertension revisited: plasma renin activity, microangiopathic hemolysis, and renal failure in malignant hypertension. Am J Hypertens 2007; 20: 900-906
32. Pitcock JA, Johnson JG, Hatch FE, Acchiardo S, Muirhead EE, Brown PS. Malignant hypertension in blacks. Malignant intrarenal arterial disease as observed by light and electron microscopy. Hum Pathol 1976; 7: 333-346
33. Kadiri S, Thomas JO. Kidney histology and clinical correlates in MHT. East Afr Med J 1993; 70: 112-116
34. Tao JL, Li H, Tang Y, Wen YB, Li XW. Lupus nephritis complicated with malignant hypertension: from renal vascular pathology to clinical relevance. Chin Med Sci J 2008; 23: 81-87
35. Glassock RJ. Current therapy in nephrology and hypertension (1984-1985). St. Louis, Missouri, United States: The CV Mosby Company 1984; pp. 324-333
36. Lip GYH, Beevers M, Beevers DG. Does renal function improve following diagnosis of malignant phase hypertension? J Hypertens 1997; 15: 1309-1315
37. Clough CG, Beevers DG, Beevers M. The survival of malignant hypertension in blacks, whites and Asians in Britain. J Hum Hypertens 1990; 4: 94-96
38. Lane DA, Lip GY, Beevers DG. Improving survival of malignant hypertension patients over 40 years. Am J Hypertens 2009; 22: 1199-1204.